New treatments for lung disease related to systemic sclerosis
Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease
['FUNDING_SBIR_2'] · EYDIS BIO, INC. · NIH-10920991
This study is testing a new treatment for people with systemic sclerosis-related lung disease, aiming to help reduce lung inflammation and scarring by targeting a specific protein, and it has shown promising results in early tests.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EYDIS BIO, INC. (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10920991 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new compounds to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD), a serious condition that causes lung fibrosis and has a high mortality rate. The study aims to target a specific protein, TAK1, which is involved in the inflammatory and fibrotic processes of the disease. By creating a potent and selective inhibitor called HS-276, the researchers hope to reduce lung inflammation and fibrosis in patients. The research involves preclinical studies that have shown promising results in reducing lung damage in models of the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic sclerosis-associated interstitial lung disease.
Not a fit: Patients with other forms of lung disease unrelated to systemic sclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients suffering from SSc-ILD.
How similar studies have performed: Other research has shown success in targeting similar pathways for treating fibrotic diseases, indicating potential for this novel approach.
Where this research is happening
DURHAM, UNITED STATES
- EYDIS BIO, INC. — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCARNEO, SCOTT — EYDIS BIO, INC.
- Study coordinator: SCARNEO, SCOTT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.